Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Tranylcypromine sulfate [USAN:USP]
RN: 13492-01-8
UNII: 7ZAT6ES870
InChIKey: BKPRVQDIOGQWTG-FKXFVUDVSA-N

Note

  • A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)

Molecular Formula

  • C9-H11-N.1/2H2-O4-S

Molecular Weight

  • 364.4636
 

Classification Codes

  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Human Data
  • Monoamine Oxidase Inhibitors

Names and Synonyms

Name of Substance

  • Tranylcypromine sulfate
  • Tranylcypromine sulfate [USAN:USP]

Synonyms

  • (+-)-trans-2-Phenylcyclopropylamine sulfate (2:1)
  • 1-Amino-2-phenylcyclopropane sulfate
  • Cyclopropanamine, 2-phenyl-, trans-(+-)-, sulfate (2:1)
  • dl-Tranylcypromine sulfate
  • EINECS 236-807-1
  • Parnate
  • Phenylcyclopromine sulfate
  • trans,DL-2-Phenylcyclopropylamine sulfate
  • Tranylcypromine sulfate
  • Tranylcypromine sulphate
  • Tylciprine
  • UNII-7ZAT6ES870

Systematic Names

  • Cyclopropanamine, 2-phenyl-, trans-(+-)-, sulfate (2:1)
  • Cyclopropylamine, 2-phenyl-, sulfate, trans-(+-)-, (2:1)
  • Tranylcypromine sulphate

Registry Numbers

CAS Registry Number

  • 13492-01-8

FDA UNII

  • 7ZAT6ES870

Other Registry Numbers

  • 1949-18-4
  • 7081-36-9

System Generated Number

  • 0013492018

Molecular Formulas

Molecular Formula

  • C9-H11-N.1/2H2-O4-S

Molecular Formula Fragments

  • C9-H11-N
  • COMPONENT
  • H2-O4-S

Structure Descriptors

InChI

1S/2C9H11N.H2O4S/c2*10-9-6-8(9)7-4-2-1-3-5-7;1-5(2,3)4/h2*1-5,8-9H,6,10H2;(H2,1,2,3,4)/t2*8-,9+;/m00./s1

InChIKey

BKPRVQDIOGQWTG-FKXFVUDVSA-N

Smiles

N[C@@H]1C[C@H]1c2ccccc2.N[C@@H]3C[C@H]3c4ccccc4.OS(=O)(=O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo oral 34mg/kg/60D-I (34mg/kg) PERIPHERAL NERVE AND SENSATION: PARESTHESIS

MUSCULOSKELETAL: JOINTS
American Journal of Psychiatry. Vol. 140, Pg. 1229, 1983.
mouse LD50 intraperitoneal 41mg/kg (41mg/kg)   European Journal of Pharmacology. Vol. 6, Pg. 115, 1969.
mouse LD50 intravenous 37mg/kg (37mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 359, 1972.
mouse LD50 oral 38mg/kg (38mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 359, 1972.
rabbit LD50 intraperitoneal 150mg/kg (150mg/kg)   British Journal of Pharmacology and Chemotherapy. Vol. 25, Pg. 158, 1965.
rat LD50 intraperitoneal 45mg/kg (45mg/kg)   Acta Biologica et Medica Germanica. Vol. 18, Pg. 617, 1967.
women TDLo oral 1200ug/kg/3D- (1.2mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION American Journal of Psychiatry. Vol. 144, Pg. 119, 1987.